Actively Recruiting
Phase 1 Study of Gene Therapy Using Lentiviral-Modified Stem Cells for Patients Aged 6-35 with Transfusion-Dependent Beta-Thalassemia
Led by Shenzhen Hemogen · Updated on 2024-10-23
8
Participants Needed
3
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial investigates the safety and effects of a gene therapy product called HGI-001 in patients with transfusion-dependent beta-thalassemia, a blood disorder requiring frequent blood transfusions. The study is a Phase 1, open-label, single-dose trial conducted across multiple centers. It focuses on using patients own modified stem cells to restore beta-globin production, which is important for healthy red blood cells. Participants aged 6 to 35 years will have their own hematopoietic stem cells collected and genetically modified with the LentiHBBT87Q system to restore beta-globin expression. After a conditioning treatment, these modified cells are infused back into the patients. The trial involves a single arm where all subjects receive this gene therapy and are followed up for two years. Throughout the study, participants will be regularly monitored with tests including blood transfusion records, imaging scans to assess iron levels in the heart and liver, hematology and bone marrow analyses, and tracking of adverse events. Researchers will measure outcomes such as transfusion independence, survival, engraftment success, and changes in hemoglobin and iron levels. Safety and efficacy data will be collected over 24 months to evaluate the therapys impact and long-term effects.
CONDITIONS
Brief Title
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
Research Team
H
Haigang Sun
L
Linxia Qian
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here